Clinical Trial Update: Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

The document announces a planned Phase 1/2 clinical trial evaluating the combination of belantamab mafodotin and elotuzumab for multiple myeloma. The study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)
• Elotuzumab (elotuzumab)

Snippet

Sponsor: Yale University | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING